1,267,618 Shares in Revolution Medicines, Inc. $RVMD Purchased by Winslow Capital Management LLC

Revolution Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Winslow Capital Management opened a major position, buying 1,267,618 Revolution Medicines shares worth about $260.2 million, or roughly 0.59% of the company.
  • Institutional investors own 94.34% of the stock. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $262.75.
  • Revolution Medicines reported quarterly EPS of -$1.90, beating the -$2.35 consensus estimate; revenue of $197.56 million also exceeded analyst expectations.
  • Interested in Revolution Medicines? Here are five stocks we like better.

Winslow Capital Management LLC purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,267,618 shares of the company's stock, valued at approximately $260,191,000. Winslow Capital Management LLC owned approximately 0.59% of Revolution Medicines at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Burkett Financial Services LLC bought a new position in shares of Revolution Medicines in the 3rd quarter valued at about $27,000. Contravisory Investment Management Inc. bought a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $32,000. Johnson Financial Group Inc. acquired a new stake in Revolution Medicines in the 2nd quarter valued at about $37,000. Silvant Capital Management LLC acquired a new stake in Revolution Medicines in the 2nd quarter valued at about $41,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Revolution Medicines during the second quarter worth about $41,000. 94.34% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on RVMD. Needham & Company LLC reissued a "buy" rating and set a $275.00 price target on shares of Revolution Medicines in a research report on Thursday, October 15th. HC Wainwright reiterated a "buy" rating and set a $350.00 target price on shares of Revolution Medicines in a research note on Tuesday, November 17th. Piper Sandler boosted their target price on Revolution Medicines from $210.00 to $222.00 and gave the stock an "overweight" rating in a report on Thursday, November 5th. Wolfe Research restated an "outperform" rating and issued a $220.00 price target on shares of Revolution Medicines in a research note on Monday, August 10th. Finally, Bank of America cut their price target on Revolution Medicines from $265.00 to $264.00 and set a "buy" rating for the company in a report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Revolution Medicines has an average rating of "Moderate Buy" and an average target price of $262.75.

View Our Latest Research Report on RVMD

Key Stories Impacting Revolution Medicines

These are some of the RVMD stories that stood out recently:

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 35,750 shares of the stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $188.10, for a total transaction of $6,724,575.00. Following the transaction, the chief financial officer owned 119,216 shares in the company, valued at $22,424,529.60. This represents a 23.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Goldsmith sold 13,988 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the transaction, the insider directly owned 253,342 shares in the company, valued at $50,475,860.08. This represents a 5.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 273,901 shares of company stock worth $53,970,418. Company insiders own 7.60% of the company's stock.

Revolution Medicines Stock Up 0.8%

RVMD opened at $160.63 on Friday. Revolution Medicines, Inc. has a fifty-two week low of $69.50 and a fifty-two week high of $224.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36. The company has a market capitalization of $34.74 billion, a P/E ratio of -17.63 and a beta of 1.44. The stock has a fifty day moving average of $190.01 and a 200-day moving average of $161.04.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, beating the consensus estimate of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to analyst estimates of $25.58 million. During the same quarter last year, the company posted ($1.61) earnings per share. On average, equities analysts expect that Revolution Medicines, Inc. will post -7.41 EPS for the current year.

Revolution Medicines Company Profile

(Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers. The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

See Also

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Revolution Medicines Right Now?

Before you consider Revolution Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.

While Revolution Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines